Cancer Family
Cutaneous Melanocytic Neoplasm
CI-CAN-00000154Explore in graph →
Non-malignant81 active trials1 approved drugs61 evidence items
- NCIt
- C7161
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000154Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06299878 | MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns](CRISTINA) | unknown | — | 72 | Russian Academy of Medical SciencesOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06246903 | INTER-PATHOLOGIST READER STUDY | unknown | — | 500 | Orlucent, IncINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04353050 | Atypical MOLes and Melanoma Early Detection Study (MoleMed)(MoleMed) | unknown | N/A | 350 | Russian Academy of Medical SciencesOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05402046 | Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms(CAMELLIA) | unknown | N/A | 605 | MelanomaPRO, RussiaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT02437279 | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients(OpACIN) | unknown | Phase 1 | 20 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT04625491 | Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor. | unknown | — | 300 | Hospital Universitario Virgen de la ArrixacaOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT03362138 | Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions(NNCD) | unknown | — | 80 | Assuta Hospital SystemsOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01729663 | Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients | unknown | Phase 2 / Phase 3 | 108 | Laboratorio Pablo Cassara S.R.L.INDUSTRY | 1 | Sep 2, 2015 | clinicaltrials |
| NCT02142335 | Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma | unknown | Phase 2 | 17 | California Cancer Assocaties for Research & ExcellenceOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00925314 | A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma | unknown | Phase 2 | 20 | Cosmo BioscienceINDUSTRY | 1 | Feb 13, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Mar 8, 2024source: clinicaltrials